isoniazid has been researched along with HIV in 50 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to the 6-month control regimen and was safe." | 9.69 | Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). ( Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z, 2023) |
| "International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1078, a randomized noninferiority study designed to compare the safety of starting isoniazid preventive therapy (IPT) in women living with human immunodeficiency virus (HIV) either during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not individual outcomes." | 9.41 | Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus. ( Aaron, L; Chakhtoura, N; Chipato, T; Gupta, A; Jean-Philippe, P; Lespinasse, D; Loftis, AJ; Masheto, G; McCarthy, K; Montepiedra, G; Nematadzira, T; Ngocho, J; Nyati, M; Onyango-Makumbi, C; Patil, S; Theron, G; Tongprasert, F; Weinberg, A; Zimmer, B, 2021) |
| "Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV." | 9.27 | Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. ( Bisson, GP; Gupta, A; Hosseinipour, MC; Hughes, MD; Kidonge, KK; Kumwenda, J; Lavenberg, JA; Miyahara, S; Ngongondo, M; Nyirenda, M; Sun, X; Torres, TS, 2018) |
| "Isoniazid did not reduce the incidence of TB in CLHIV." | 8.98 | Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. ( Charan, J; Emmanuel, P; Goyal, JP; Kumar, A; Patel, A; Reljic, T, 2018) |
| "Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI)." | 8.31 | High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. ( Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y, 2023) |
| "Rifampin appears to be safe and as effective as isoniazid across many populations with health conditions, including HIV." | 8.02 | Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. ( Al-Jahdali, H; Bah, B; Belo, M; Campbell, JR; Cook, VJ; Long, R; Menzies, D; Schwartzman, K; Trajman, A, 2021) |
| "Isoniazid preventive therapy (IPT) against tuberculosis (TB) is a life-saving intervention for people living with HIV (PLHIV)." | 8.02 | Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). ( Auld, AF; Gunde, LJ; Jahn, A; Kirking, HL; Maida, A; Nabity, SA; Nyirenda, RK; Odo, M; Oeltmann, JE; Shiraishi, RW; Surie, D, 2021) |
| "Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 7.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 7.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| "Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of isoniazid preventive therapy (IPT)." | 7.77 | Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. ( Cohen, T; Jenkins, HE; Zignol, M, 2011) |
| "As part of a research directed to the synthesis of novel isoniazid derivatives with potential activity on mycobacteria and HIV virus, the acetophenone-isonicotinoylhydrazones 3 and the 4-aryl-1-methoxy-1-(4-pyridyl)- 2,3-diaza-1,3-butadienes 5, obtained by reaction between isonicotinoylhydrazones and diazomethane, have been prepared and tested for such activities." | 7.69 | Halogenated isoniazid derivatives as possible antimycobacterial and anti-HIV agents--III. ( Gabbrielli, G; Maccari, R; Ottanà, R; Pizzimenti, FC; Vigorita, MG; Zappalà, C, 1994) |
| "Cumulative 24-month Mycobacterium tuberculosis infection incidence (measured primarily by tuberculin skin test [TST]) was high among human immunodeficiency virus exposed but uninfected infants (8." | 7.11 | Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial. ( Carimo, N; Cranmer, LM; Escudero, JN; Hawn, TR; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Mecha, J; Richardson, BA; Warr, AJ, 2022) |
| "In LBW/preterm infants, INH dosing needs frequent adjustment to account for growth and maturation." | 5.72 | Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. ( Bekker, A; Béranger, A; Browning, R; Cababasay, M; Capparelli, EV; Cotton, MF; Mirochnick, M; Moye, J; Savic, RM; Solans, BP; Violari, A; Wang, J; Wiesner, L, 2022) |
| "In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to the 6-month control regimen and was safe." | 5.69 | Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). ( Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z, 2023) |
| " We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol." | 5.41 | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. ( Béranger, A; Gegia, M; Linh, NN; Mirzayev, F; Mohamed, A; Nahid, P; Radtke, K; Savic, RM; Schumacher, SG; Solans, BP, 2023) |
| "International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1078, a randomized noninferiority study designed to compare the safety of starting isoniazid preventive therapy (IPT) in women living with human immunodeficiency virus (HIV) either during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not individual outcomes." | 5.41 | Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus. ( Aaron, L; Chakhtoura, N; Chipato, T; Gupta, A; Jean-Philippe, P; Lespinasse, D; Loftis, AJ; Masheto, G; McCarthy, K; Montepiedra, G; Nematadzira, T; Ngocho, J; Nyati, M; Onyango-Makumbi, C; Patil, S; Theron, G; Tongprasert, F; Weinberg, A; Zimmer, B, 2021) |
| "Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs." | 5.32 | Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. ( Amofa, J; Driver, CR; Fujiwara, PI; Gourevitch, MN; Highley, E; Kaye, K; Munsiff, SS; Rubino, MA; Scholten, JN; Seewald, R; Trim, C, 2003) |
| "Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV." | 5.27 | Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. ( Bisson, GP; Gupta, A; Hosseinipour, MC; Hughes, MD; Kidonge, KK; Kumwenda, J; Lavenberg, JA; Miyahara, S; Ngongondo, M; Nyirenda, M; Sun, X; Torres, TS, 2018) |
| "South African guidelines recommend protease-inhibitor-based antiretroviral therapy (ART) with lopinavir-ritonavir for human immunodeficiency virus (HIV)-infected children <36 months of age." | 5.14 | Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. ( Abrams, EJ; Coovadia, A; Ko, S; Kuhn, L; Meyers, T; Reitz, C; Sherman, G; Strehlau, R, 2010) |
| "Although isoniazid (INH) preventive therapy (IPT) can reduce the risk of active TB among HIV-infected individuals, preventive therapy is rarely used in developing countries." | 5.11 | INH preventive therapy among adult HIV-infected patients in Thailand. ( Hiransuthikul, N; Hiransuthikul, P; Nelson, KE; Paewplot, R; Vorayingyong, A, 2005) |
| "Isoniazid did not reduce the incidence of TB in CLHIV." | 4.98 | Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. ( Charan, J; Emmanuel, P; Goyal, JP; Kumar, A; Patel, A; Reljic, T, 2018) |
| "Because treatment can only be initiated when infection is detected, and is guided by the results of antimicrobial susceptibility testing, there recently has been a marked increase in the development and testing of novel assays designed to detect Mycobacterium tuberculosis complex, with or without simultaneous detection of resistance to isoniazid and/or rifampin." | 4.89 | Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing. ( Wilson, ML, 2013) |
| "Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI)." | 4.31 | High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. ( Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y, 2023) |
| "We used nonlinear mixed-effects modeling to characterize the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide, and investigated the association of human immunodeficiency virus (HIV), antiretroviral therapy (ART), drug formulation, age, and body size with their pharmacokinetics." | 4.31 | Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. ( Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H, 2023) |
| "Rifampin appears to be safe and as effective as isoniazid across many populations with health conditions, including HIV." | 4.02 | Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. ( Al-Jahdali, H; Bah, B; Belo, M; Campbell, JR; Cook, VJ; Long, R; Menzies, D; Schwartzman, K; Trajman, A, 2021) |
| "Isoniazid preventive therapy (IPT) against tuberculosis (TB) is a life-saving intervention for people living with HIV (PLHIV)." | 4.02 | Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). ( Auld, AF; Gunde, LJ; Jahn, A; Kirking, HL; Maida, A; Nabity, SA; Nyirenda, RK; Odo, M; Oeltmann, JE; Shiraishi, RW; Surie, D, 2021) |
| "Isoniazid preventive therapy (IPT) is widely used to protect against tuberculosis (TB) in people living with human immunodeficiency virus (HIV)." | 3.96 | Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data. ( Boulle, A; Cohen, K; Davies, MA; de Waal, R; Heekes, A; Jacob, N; Kalk, E; Maartens, G; Mehta, U; Myer, L, 2020) |
| "31) were associated with increased risk of tuberculosis whereas taking Isoniazid Preventive Therapy (IPT) (AHR = 0." | 3.96 | Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study. ( Aemro, A; Anlay, DZ; Jember, A, 2020) |
| " The secondary objective was to determine the overall incidence of hepatitis in children on Anti tubercular treatment (ATT) and isoniazid prophylactic therapy (IPT)." | 3.91 | Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children. ( Indumathi, CK; Jain, S; Krishnamurthy, S; Sethuraman, A, 2019) |
| "Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 3.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 3.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| "Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of isoniazid preventive therapy (IPT)." | 3.77 | Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. ( Cohen, T; Jenkins, HE; Zignol, M, 2011) |
| "Cumulative 24-month Mycobacterium tuberculosis infection incidence (measured primarily by tuberculin skin test [TST]) was high among human immunodeficiency virus exposed but uninfected infants (8." | 3.11 | Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial. ( Carimo, N; Cranmer, LM; Escudero, JN; Hawn, TR; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Mecha, J; Richardson, BA; Warr, AJ, 2022) |
| "There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ." | 2.82 | Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ( Bekker, A; Donald, PR; Draper, HR; Hesseling, AC; McIlleron, HM; Murray, S; Schaaf, HS; van der Laan, L; Wiesner, L, 2016) |
| "In LBW/preterm infants, INH dosing needs frequent adjustment to account for growth and maturation." | 1.72 | Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. ( Bekker, A; Béranger, A; Browning, R; Cababasay, M; Capparelli, EV; Cotton, MF; Mirochnick, M; Moye, J; Savic, RM; Solans, BP; Violari, A; Wang, J; Wiesner, L, 2022) |
| "The frequency of late recurrences following treatment completion has not been well-studied." | 1.37 | When tuberculosis comes back: who develops recurrent tuberculosis in california? ( Deriemer, K; Flood, JM; Pascopella, L; Watt, JP, 2011) |
| "Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs." | 1.32 | Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. ( Amofa, J; Driver, CR; Fujiwara, PI; Gourevitch, MN; Highley, E; Kaye, K; Munsiff, SS; Rubino, MA; Scholten, JN; Seewald, R; Trim, C, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.00) | 18.2507 |
| 2000's | 5 (10.00) | 29.6817 |
| 2010's | 27 (54.00) | 24.3611 |
| 2020's | 17 (34.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, D | 1 |
| Yogeeswari, P | 1 |
| Bhat, P | 1 |
| Thomas, A | 1 |
| Srividya, M | 1 |
| Sriram, D | 1 |
| Béranger, A | 2 |
| Bekker, A | 2 |
| Solans, BP | 2 |
| Cotton, MF | 4 |
| Mirochnick, M | 1 |
| Violari, A | 2 |
| Wang, J | 1 |
| Cababasay, M | 1 |
| Wiesner, L | 4 |
| Browning, R | 1 |
| Moye, J | 1 |
| Capparelli, EV | 1 |
| Savic, RM | 3 |
| LaCourse, SM | 3 |
| Escudero, JN | 3 |
| Mecha, J | 2 |
| Warr, AJ | 3 |
| Richardson, BA | 3 |
| Carimo, N | 1 |
| Cranmer, LM | 3 |
| Maleche-Obimbo, E | 3 |
| Matemo, D | 3 |
| Kinuthia, J | 3 |
| Hawn, TR | 3 |
| John-Stewart, G | 2 |
| Pettit, AC | 1 |
| Phillips, PPJ | 1 |
| Kurbatova, E | 1 |
| Vernon, A | 1 |
| Nahid, P | 2 |
| Dawson, R | 1 |
| Dooley, KE | 3 |
| Sanne, I | 1 |
| Waja, Z | 2 |
| Mohapi, L | 2 |
| Podany, AT | 1 |
| Samaneka, W | 1 |
| Johnson, JL | 1 |
| Muzanyi, G | 1 |
| Lalloo, UG | 1 |
| Bryant, K | 1 |
| Sizemore, E | 1 |
| Scott, N | 1 |
| Dorman, SE | 1 |
| Chaisson, RE | 4 |
| Swindells, S | 2 |
| Radtke, K | 1 |
| Mohamed, A | 1 |
| Mirzayev, F | 1 |
| Gegia, M | 1 |
| Linh, NN | 1 |
| Schumacher, SG | 1 |
| Jarrett, RT | 1 |
| van der Heijden, Y | 1 |
| Shotwell, MS | 1 |
| Chihota, V | 1 |
| Marzinke, MA | 1 |
| Churchyard, GJ | 1 |
| Sekayi, W | 1 |
| Namyalo, E | 1 |
| Namayanja, J | 1 |
| Kungu, JM | 1 |
| Galileya, LT | 1 |
| Wasmann, RE | 1 |
| Chabala, C | 1 |
| Rabie, H | 1 |
| Lee, J | 1 |
| Njahira Mukui, I | 1 |
| Hesseling, A | 1 |
| Zar, H | 1 |
| Aarnoutse, R | 1 |
| Turkova, A | 1 |
| Gibb, D | 1 |
| McIlleron, H | 3 |
| Denti, P | 3 |
| Stout, JE | 1 |
| Sterling, TR | 1 |
| Horsburgh, CR | 1 |
| Ramchandani, R | 1 |
| Salazar-Austin, N | 1 |
| Cohn, S | 1 |
| Lala, S | 1 |
| Hoffmann, CJ | 1 |
| Martinson, N | 1 |
| Kalk, E | 1 |
| Heekes, A | 1 |
| Mehta, U | 1 |
| de Waal, R | 1 |
| Jacob, N | 1 |
| Cohen, K | 1 |
| Myer, L | 1 |
| Davies, MA | 1 |
| Maartens, G | 2 |
| Boulle, A | 2 |
| Schutz, C | 1 |
| Chirehwa, M | 1 |
| Barr, D | 1 |
| Ward, A | 1 |
| Janssen, S | 2 |
| Burton, R | 1 |
| Wilkinson, RJ | 1 |
| Shey, M | 1 |
| Meintjes, G | 2 |
| John-Stewart, GC | 1 |
| Aemro, A | 1 |
| Jember, A | 1 |
| Anlay, DZ | 1 |
| Campbell, JR | 1 |
| Al-Jahdali, H | 1 |
| Bah, B | 1 |
| Belo, M | 1 |
| Cook, VJ | 1 |
| Long, R | 1 |
| Schwartzman, K | 1 |
| Trajman, A | 1 |
| Menzies, D | 1 |
| Theron, G | 1 |
| Montepiedra, G | 1 |
| Aaron, L | 1 |
| McCarthy, K | 1 |
| Chakhtoura, N | 1 |
| Jean-Philippe, P | 1 |
| Zimmer, B | 1 |
| Loftis, AJ | 1 |
| Chipato, T | 1 |
| Nematadzira, T | 1 |
| Nyati, M | 1 |
| Onyango-Makumbi, C | 1 |
| Masheto, G | 1 |
| Ngocho, J | 1 |
| Tongprasert, F | 1 |
| Patil, S | 1 |
| Lespinasse, D | 1 |
| Weinberg, A | 1 |
| Gupta, A | 3 |
| Nabity, SA | 1 |
| Gunde, LJ | 1 |
| Surie, D | 1 |
| Shiraishi, RW | 1 |
| Kirking, HL | 1 |
| Maida, A | 1 |
| Auld, AF | 1 |
| Odo, M | 1 |
| Jahn, A | 1 |
| Nyirenda, RK | 1 |
| Oeltmann, JE | 1 |
| Krishnan, S | 1 |
| Queiroz, ATL | 1 |
| Gupte, N | 1 |
| Bisson, GP | 2 |
| Kumwenda, J | 2 |
| Naidoo, K | 1 |
| Mave, V | 1 |
| Mngqibisa, R | 1 |
| Lama, JR | 1 |
| Hosseinipour, MC | 2 |
| Andrade, BB | 1 |
| Karakousis, PC | 1 |
| Tashiro, K | 1 |
| Horita, N | 1 |
| Nagai, K | 1 |
| Ikeda, M | 1 |
| Shinkai, M | 1 |
| Yamamoto, M | 1 |
| Sato, T | 1 |
| Hara, Y | 1 |
| Nagakura, H | 1 |
| Shibata, Y | 1 |
| Watanabe, H | 1 |
| Nakashima, K | 1 |
| Ushio, R | 1 |
| Nagashima, A | 1 |
| Narita, A | 1 |
| Kobayashi, N | 1 |
| Kudo, M | 1 |
| Kaneko, T | 1 |
| van der Laan, LE | 1 |
| Garcia-Prats, AJ | 1 |
| Schaaf, HS | 4 |
| Tikiso, T | 1 |
| de Kock, M | 1 |
| Winckler, J | 1 |
| Norman, J | 1 |
| Hesseling, AC | 3 |
| Charan, J | 1 |
| Goyal, JP | 1 |
| Reljic, T | 1 |
| Emmanuel, P | 1 |
| Patel, A | 1 |
| Kumar, A | 1 |
| Ngongondo, M | 1 |
| Miyahara, S | 1 |
| Hughes, MD | 1 |
| Sun, X | 1 |
| Lavenberg, JA | 1 |
| Torres, TS | 1 |
| Nyirenda, M | 1 |
| Kidonge, KK | 1 |
| Pasipanodya, JG | 1 |
| Gumbo, T | 1 |
| Baker, BJ | 1 |
| Zhao, Y | 1 |
| Fox, T | 1 |
| Manning, K | 1 |
| Stewart, A | 1 |
| Tiffin, N | 1 |
| Khomo, N | 1 |
| Leslie, J | 1 |
| Mudaly, V | 1 |
| Kock, Y | 1 |
| Wasserman, S | 1 |
| Alffenaar, JC | 1 |
| Heysell, SK | 1 |
| Mpagama, SG | 1 |
| Indumathi, CK | 1 |
| Sethuraman, A | 1 |
| Jain, S | 1 |
| Krishnamurthy, S | 1 |
| Walsh, KF | 1 |
| Souroutzidis, A | 1 |
| Vilbrun, SC | 1 |
| Peeples, M | 1 |
| Joissaint, G | 1 |
| Delva, S | 1 |
| Widmann, P | 1 |
| Royal, G | 1 |
| Pry, J | 1 |
| Bang, H | 1 |
| Pape, JW | 1 |
| Koenig, SP | 1 |
| Gezae, KE | 1 |
| Abebe, HT | 1 |
| Gebretsadik, LG | 1 |
| Saunders, MJ | 1 |
| Evans, CA | 1 |
| Wilson, ML | 1 |
| van Griensven, J | 1 |
| Choun, K | 1 |
| Chim, B | 1 |
| Thai, S | 1 |
| Lorent, N | 1 |
| Lynen, L | 1 |
| Ayele, HT | 1 |
| Mourik, MS | 1 |
| Debray, TP | 1 |
| Bonten, MJ | 1 |
| Draper, HR | 1 |
| van der Laan, L | 1 |
| Murray, S | 1 |
| Donald, PR | 1 |
| McIlleron, HM | 1 |
| Bélard, S | 1 |
| Remppis, J | 1 |
| Bootsma, S | 1 |
| Kombila, DU | 1 |
| Beyeme, JO | 1 |
| Rossatanga, EG | 1 |
| Kokou, C | 1 |
| Osbak, KK | 1 |
| Obiang Mba, RM | 1 |
| Kaba, HM | 1 |
| Traoré, AN | 1 |
| Ehrhardt, J | 1 |
| Bache, EB | 1 |
| Flamen, A | 1 |
| Rüsch-Gerdes, S | 1 |
| Frank, M | 1 |
| Adegnika, AA | 1 |
| Lell, B | 1 |
| Niemann, S | 1 |
| Kremsner, PG | 1 |
| Loembé, MM | 1 |
| Alabi, AS | 1 |
| Grobusch, MP | 1 |
| Aung, NM | 1 |
| Hanson, J | 1 |
| Kyi, TT | 1 |
| Htet, ZW | 1 |
| Cooper, DA | 1 |
| Boyd, MA | 1 |
| Kyi, MM | 1 |
| Saw, HA | 1 |
| Munseri, PJ | 1 |
| Talbot, EA | 1 |
| Mtei, L | 1 |
| Fordham von Reyn, C | 1 |
| Reitz, C | 1 |
| Coovadia, A | 1 |
| Ko, S | 1 |
| Meyers, T | 1 |
| Strehlau, R | 1 |
| Sherman, G | 1 |
| Kuhn, L | 1 |
| Abrams, EJ | 1 |
| Cohen, T | 2 |
| Murray, M | 1 |
| Wallengren, K | 1 |
| Alvarez, GG | 1 |
| Samuel, EY | 1 |
| Wilson, D | 1 |
| Jenkins, HE | 1 |
| Zignol, M | 1 |
| Pascopella, L | 1 |
| Deriemer, K | 1 |
| Watt, JP | 1 |
| Flood, JM | 1 |
| Kim, S | 1 |
| Madhi, S | 1 |
| Nachman, S | 1 |
| Victor, TC | 1 |
| McSherry, G | 1 |
| Mitchell, C | 1 |
| Shaweno, D | 1 |
| Worku, A | 1 |
| Scholten, JN | 1 |
| Driver, CR | 1 |
| Munsiff, SS | 1 |
| Kaye, K | 1 |
| Rubino, MA | 1 |
| Gourevitch, MN | 1 |
| Trim, C | 1 |
| Amofa, J | 1 |
| Seewald, R | 1 |
| Highley, E | 1 |
| Fujiwara, PI | 1 |
| Hiransuthikul, N | 1 |
| Nelson, KE | 1 |
| Hiransuthikul, P | 1 |
| Vorayingyong, A | 1 |
| Paewplot, R | 1 |
| Vigorita, MG | 1 |
| Ottanà, R | 1 |
| Zappalà, C | 1 |
| Maccari, R | 1 |
| Pizzimenti, FC | 1 |
| Gabbrielli, G | 1 |
| Gie, RP | 1 |
| van Rie, A | 1 |
| Seifart, HI | 1 |
| van Helden, PD | 1 |
| Mac-Arthur, A | 1 |
| Gloyd, S | 1 |
| Perdigão, P | 1 |
| Noya, A | 1 |
| Sacarlal, J | 1 |
| Kreiss, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants[NCT02613169] | Phase 2 | 300 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| A Randomized Trial to Compare Effectiveness of 4 Months Rifampin (4 RIF) With 9 Months Isoniazid (9 INH) in the Prevention of Active TB in Children: The P4v9 Trial[NCT00170209] | Phase 3 | 844 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness[NCT00931736] | Phase 3 | 6,031 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)[NCT01637558] | Phase 4 | 200 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Pilot Study to Evaluate Video Observed Treatment Among Tuberculosis Patients From Lambaréné Using an Instant Messenger Application[NCT05865626] | 30 participants (Actual) | Interventional | 2018-10-10 | Completed | |||
| DARDAR Health Project (Disseminated Tuberculosis and HIV Infection)[NCT00052195] | Phase 2/Phase 3 | 1,975 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Z 31411 - The Effect of Xpert MTB/RIF on Patient Health Outcomes and Empirical TB Treatment Among Persons Living With HIV/AIDS: A Parallel-Group Prospective Cohort Study Under Real-World Conditions in Lusaka, Zambia[NCT02729532] | 776 participants (Actual) | Observational | 2016-06-22 | Completed | |||
| Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056] | 360 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of infants with a combined endpoint of MTB infection, TB disease, and death~MTB infection as measured by IGRA or tuberculin skin test at 12 months post-enrollment~TB disease including microbiologically confirmed (culture or Xpert positive), or probable TB (clinical diagnosis).~Death of infant" (NCT02613169)
Timeframe: Over 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Isoniazid | 11 |
| No Isoniazid | 19 |
Among HEU infants enrolled at approximately 6 weeks of age, compare the risk of acquiring MTB infection during 1 year of follow-up in infants randomized to receive INH vs. no INH using an interferon-gamma release (IGRA) QuantiFERON-TB Gold Plus (QFT-Plus) assay or tuberculin skin test as part of a composite endpoint to determine MTB infection status (NCT02613169)
Timeframe: at 12 months post randomization
| Intervention | participants (Number) |
|---|---|
| Isoniazid | 10 |
| No Isoniazid | 18 |
Among HEU infants enrolled at approximately 6 weeks of age, compare the risk of acquiring MTB infection during 1 year of follow-up in infants randomized to receive INH vs. no INH using an interferon-gamma release (IGRA) QuantiFERON-TB Gold Plus (QFT-Plus) assay or tuberculin skin test as part of a composite endpoint to determine MTB infection status (NCT02613169)
Timeframe: at 12 months post randomization
| Intervention | TB infections/100 person years (Number) |
|---|---|
| Isoniazid | 7.0 |
| No Isoniazid | 13.4 |
Number of infants with grade 3 or higher treatment-related adverse events as assessed by DAIDS Table for the Grading Severity of Pediatric Adverse Experiences (NCT02613169)
Timeframe: Over 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Isoniazid | 21 |
| No Isoniazid | 16 |
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | percent (Number) |
|---|---|
| INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
| Intervention | pmol/mg (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
| Intervention | days (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 3 months72558043 | At 6 months72558043 | |||||||||||
| Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
| INH and Vitamin B6 | 160 | |||||||||||
| INH and Vitamin B6 | 79 | |||||||||||
| INH and Vitamin B6 | 38 | |||||||||||
| INH and Vitamin B6 | 2 | |||||||||||
| INH and Vitamin B6 | 124 | |||||||||||
| INH and Vitamin B6 | 90 | |||||||||||
| INH and Vitamin B6 | 41 | |||||||||||
| INH and Vitamin B6 | 4 | |||||||||||
| INH and Vitamin B6 | 0 | |||||||||||
| INH and Vitamin B6 | 1 | |||||||||||
4 reviews available for isoniazid and HIV
| Article | Year |
|---|---|
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Ethambutol; HIV; HIV Infections; Humans; Isoniazid; | 2023 |
Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis.
Topics: Antitubercular Agents; Child; HIV; HIV Infections; Humans; Isoniazid; Randomized Controlled Trials a | 2018 |
Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; Coinfection; | 2013 |
Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.
Topics: Antitubercular Agents; HIV; HIV Infections; Humans; Isoniazid; Randomized Controlled Trials as Topic | 2015 |
13 trials available for isoniazid and HIV
| Article | Year |
|---|---|
Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial.
Topics: Antitubercular Agents; Child, Preschool; Follow-Up Studies; HIV; HIV Infections; Humans; Incidence; | 2022 |
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxac | 2023 |
Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent
Topics: Antitubercular Agents; Female; HIV; HIV Infections; Humans; Incidence; Infant; Isoniazid; Kenya; Mal | 2020 |
A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.
Topics: Antitubercular Agents; HIV; HIV Infections; Humans; Infant; Isoniazid; Kenya; Mycobacterium tubercul | 2021 |
Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus.
Topics: Adolescent; Child; Female; HIV; HIV Infections; Humans; Infant, Newborn; Isoniazid; Pregnancy; Pregn | 2021 |
Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Biomark | 2021 |
HbA1c level cannot predict the treatment outcome of smear-positive non-multi-drug-resistant HIV-negative pulmonary tuberculosis inpatients.
Topics: Adult; Aged; Aged, 80 and over; Female; Glycated Hemoglobin; HIV; Humans; Isoniazid; Male; Middle Ag | 2017 |
Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antitubercular Agents; Aspartate Aminotransfera | 2018 |
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Topics: Anti-Bacterial Agents; Area Under Curve; Coinfection; Drug Dosage Calculations; Ethambutol; Female; | 2016 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Child, Preschool; Drug Therapy, Combin | 2010 |
High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double | 2012 |
INH preventive therapy among adult HIV-infected patients in Thailand.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Female; Follow | 2005 |
33 other studies available for isoniazid and HIV
| Article | Year |
|---|---|
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; I | 2011 |
Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Child, Preschool; Genotype; HIV; HIV Infection | 2022 |
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Weight; Drug Therapy, Combination; | 2023 |
Prevalence and predictors of tuberculosis among HIV patients who completed isoniazid preventive therapy (IPT) at Reach out Mbuya community health initiative.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; HIV; HIV Infections; HIV Seropositivity; Huma | 2023 |
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Huma | 2023 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply.
Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
Isoniazid Preventive Therapy and Pregnancy Outcomes in Women Living With Human Immunodeficiency Virus in the Tshepiso Cohort.
Topics: Antitubercular Agents; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Preg | 2020 |
Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data.
Topics: Antitubercular Agents; Female; HIV; HIV Infections; Humans; Isoniazid; Pregnancy; Pregnant Women; So | 2020 |
Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis.
Topics: Adult; Antitubercular Agents; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Tu | 2020 |
Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Age | 2020 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antitubercular Agents; Child; Child, Preschool; Femal | 2021 |
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug | 2018 |
Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?
Topics: Antitubercular Agents; Coinfection; Drug Monitoring; HIV; HIV Infections; Humans; Isoniazid; Rifampi | 2018 |
ART and lifelong IPT for health care workers with HIV: a priority for infection control.
Topics: Adolescent; Botswana; Health Personnel; HIV; Humans; Infection Control; Isoniazid; Middle Aged; Tube | 2018 |
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; E | 2019 |
Therapeutic Drug Monitoring: The Need for Practical Guidance.
Topics: Coinfection; Drug Monitoring; HIV; HIV Infections; Humans; Isoniazid; Rifampin; Sputum; Tuberculosis | 2019 |
Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 2019 |
Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethiona | 2019 |
Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009-2016: survival model approach.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Coinfection; Ethiopia; Female; HIV; HIV Infec | 2019 |
Ending Tuberculosis through Prevention.
Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactio | 2015 |
Tuberculosis Treatment Outcome and Drug Resistance in Lambaréné, Gabon: A Prospective Cohort Study.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Coinfection; Drug Resistance, Mul | 2016 |
HIV care in Yangon, Myanmar; successes, challenges and implications for policy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Posit | 2017 |
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte | 2010 |
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte | 2010 |
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte | 2010 |
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte | 2010 |
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009.
Topics: Adult; Antitubercular Agents; Comorbidity; Directly Observed Therapy; HIV; HIV Infections; Humans; I | 2011 |
When tuberculosis comes back: who develops recurrent tuberculosis in california?
Topics: Adult; Antitubercular Agents; California; Drug Therapy, Combination; Female; HIV; HIV Infections; Hu | 2011 |
Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Drug Administration Schedule; Fem | 2012 |
Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV; HIV Infectio | 2003 |
Halogenated isoniazid derivatives as possible antimycobacterial and anti-HIV agents--III.
Topics: Antiviral Agents; Cell Line; HIV; Hydrocarbons, Halogenated; Isoniazid; Microbial Sensitivity Tests; | 1994 |
Second episode of tuberculosis in an HIV-infected child: relapse or reinfection?
Topics: AIDS-Related Opportunistic Infections; Amoxicillin-Potassium Clavulanate Combination; Antibiotics, A | 2000 |
Characteristics of drug resistance and HIV among tuberculosis patients in Mozambique.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antibiotics, Antitubercular; Child; Child, Pr | 2001 |